Rhenman & Partners Asset Management Ab Upped Its Nektar Therapeutics (NKTR) Holding

November 10, 2018 - By Linda Rogers

Nektar Therapeutics (NASDAQ:NKTR) LogoInvestors sentiment decreased to 1.13 in 2018 Q2. Its down 0.30, from 1.43 in 2018Q1. It turned negative, as 54 investors sold NKTR shares while 100 reduced holdings. 82 funds opened positions while 92 raised stakes. 157.21 million shares or 2.48% more from 153.40 million shares in 2018Q1 were reported. Teachers Retirement Systems Of The State Of Kentucky holds 30,500 shares or 0.02% of its portfolio. Parametric Portfolio Associate Limited Liability Company has invested 0.01% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Asset Mgmt Incorporated reported 0.03% of its portfolio in Nektar Therapeutics (NASDAQ:NKTR). Sabby Mngmt Ltd Liability Company holds 1.83% or 241,922 shares in its portfolio. Pnc Financial Services Grp has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). State Of Alaska Department Of Revenue holds 42,960 shares or 0.04% of its portfolio. Hartford Invest invested in 0.03% or 20,415 shares. Tobam holds 486,336 shares or 0.98% of its portfolio. The Iowa-based Cambridge Advsrs Inc has invested 0% in Nektar Therapeutics (NASDAQ:NKTR). State Of New Jersey Common Pension Fund D has 105,000 shares for 0.02% of their portfolio. Profund Advisors Ltd Liability Corporation has invested 0.1% in Nektar Therapeutics (NASDAQ:NKTR). Blackrock Incorporated reported 12.66M shares. University Of Notre Dame Du Lac accumulated 32,960 shares or 0.31% of the stock. Bnp Paribas Arbitrage Sa invested in 192,804 shares or 0% of the stock. Trexquant Investment Limited Partnership holds 0.25% in Nektar Therapeutics (NASDAQ:NKTR) or 74,911 shares.

Since May 16, 2018, it had 1 insider buy, and 21 selling transactions for $18.63 million activity. Nicholson John had sold 4,917 shares worth $410,029 on Wednesday, May 16. Doberstein Stephen K had sold 3,435 shares worth $286,445. CHESS ROBERT sold $551,600 worth of stock. 9,000 shares were sold by Lingnau Lutz, worth $512,820. Shares for $290,212 were bought by WHITFIELD ROY A on Tuesday, June 5. $298,203 worth of Nektar Therapeutics (NASDAQ:NKTR) shares were sold by Thomsen Jillian B..

Rhenman & Partners Asset Management Ab increased its stake in Nektar Therapeutics (NKTR) by 197.72% based on its latest 2018Q2 regulatory filing with the SEC. Rhenman & Partners Asset Management Ab bought 410,194 shares as the company’s stock rose 17.51% with the market. The institutional investor held 617,652 shares of the major pharmaceuticals company at the end of 2018Q2, valued at $30.16M, up from 207,458 at the end of the previous reported quarter. Rhenman & Partners Asset Management Ab who had been investing in Nektar Therapeutics for a number of months, seems to be bullish on the $5.87 billion market cap company. The stock decreased 3.65% or $1.29 during the last trading session, reaching $34.02. About 2.90M shares traded or 29.91% up from the average. Nektar Therapeutics (NASDAQ:NKTR) has risen 187.03% since November 10, 2017 and is uptrending. It has outperformed by 171.41% the S&P500.

Rhenman & Partners Asset Management Ab, which manages about $977.11 million US Long portfolio, decreased its stake in Abbvie Inc (NYSE:ABBV) by 136,700 shares to 70,000 shares, valued at $6.49 million in 2018Q2, according to the filing. It also reduced its holding in Glaukos Corp by 143,400 shares in the quarter, leaving it with 360,000 shares, and cut its stake in Biogen Inc (NASDAQ:BIIB).

More notable recent Nektar Therapeutics (NASDAQ:NKTR) news were published by: Gurufocus.com which released: “Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Nektar Therapeutics – NKTR” on November 10, 2018, also Globenewswire.com with their article: “CLASS ACTION UPDATE for TGTX, HAS and NKTR: Levi & Korsinsky, LLP Reminds Investors of Class Actions on …” published on October 31, 2018, Businesswire.com published: “Kessler Topaz Meltzer & Check, LLP – Reminds Investors of Securities Fraud Class Action Lawsuit Against Nektar …” on November 08, 2018. More interesting news about Nektar Therapeutics (NASDAQ:NKTR) were released by: Seekingalpha.com and their article: “Key events next week – healthcare” published on November 02, 2018 as well as Streetinsider.com‘s news article titled: “Nektar Therapeutics (NKTR) PT Lowered to $81 at Mizuho Securities” with publication date: November 08, 2018.

Nektar Therapeutics (NASDAQ:NKTR) Ratings Coverage

Among 6 analysts covering Nektar Therapeutics (NASDAQ:NKTR), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Nektar Therapeutics has $10100 highest and $54 lowest target. $80’s average target is 135.16% above currents $34.02 stock price. Nektar Therapeutics had 7 analyst reports since May 11, 2018 according to SRatingsIntel. The stock has “Buy” rating by Canaccord Genuity on Tuesday, June 5. Jefferies maintained the shares of NKTR in report on Thursday, November 8 with “Buy” rating. The stock of Nektar Therapeutics (NASDAQ:NKTR) has “Buy” rating given on Friday, May 11 by Canaccord Genuity. The rating was downgraded by H.C. Wainwright on Monday, June 11 to “Neutral”. The firm has “Buy” rating given on Monday, June 4 by Cowen & Co. The firm has “Overweight” rating by JP Morgan given on Monday, June 4.

Nektar Therapeutics (NASDAQ:NKTR) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>